Evidence map›Paper›PMID 27416843›Full record

ArticleBMC neurology2016

Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC).

Robert Zivadinov, Diane L Cookfair, Lauren Krupp, Aaron E Miller, Neil Lava, Patricia K Coyle, Andrew D Goodman, Burk Jubelt, Michael Lenihan, Joseph Herbert and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Robert ZivadinovBuffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. rzivadinov@bnac.net.
Diane L CookfairDepartment of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, 100 High Street, Buffalo, NY, 14203, USA.
Lauren KruppDepartment of Neurology, Stony Brook University Medical Center, Stony Brook, NY, USA.
Aaron E MillerThe Corinne Goldsmith Dickinson Center of Multiple Sclerosis, Mount Sinai School of Medicine, New York, NY, USA.
Neil LavaDepartment of Neurology, Albany Medical School, Multiple Sclerosis Center, Albany, NY, USA.
Patricia K CoyleDepartment of Neurology, Stony Brook University Medical Center, Stony Brook, NY, USA.
Andrew D GoodmanDepartment of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
Burk JubeltDepartment of Neurology, SUNY Upstate Medical University, Syracuse, NY, USA.
Michael LenihanAdirondack Neurology Associates, Glens Falls, NY, USA.
Joseph HerbertDepartment of Neurology, NYU School of Medicine, New York, NY, USA.
Malcolm GottesmanDepartment of Neuroscience, Winthrop University Hospital, Mineola, NY, USA.
David H SnyderDepartment of Neurology, Weill Medical College of Cornell University, New York, NY, USA.
Brian R ApatoffMultiple Sclerosis Center, New York, NY, USA.
Barbara E TeterDepartment of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, 100 High Street, Buffalo, NY, 14203, USA.
Allan B PerelAlpha Neurology, Staten Island, NY, USA.
Frederick MunschauerDepartment of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, 100 High Street, Buffalo, NY, 14203, USA.
Bianca Weinstock-GuttmanDepartment of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, 100 High Street, Buffalo, NY, 14203, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis retrospective analysis explored prognostic factors associated with a benign multiple sclerosis (BMS) disease course at baseline and over the 4-year follow-up.

methodsPatients from the centralized New York State Multiple Sclerosis Consortium registry were classified as having BMS according to 3 different criteria centered on disease duration and disability. Additional analyses explored prognostic factors associated with BMS using the most conservative disability criteria (Expanded Disability Status Scale ≤2 and disease duration ≥10 years).

resultsAmong 6258 patients who fulfilled eligibility criteria, 19.8 % to 33.3 % were characterized as having BMS, at baseline depending on classification criteria used. Positive prognostic factors for BMS at baseline included female sex (p < 0.0001) and younger age at onset (p < 0.0001); negative prognostic factors included progressive-onset type of MS and African-American race. Of the 1237 BMS patients (per most conservative criteria), 742 were followed for a median of 4 years to explore effect of disease-modifying treatment (DMT) on benign status. DMT (p = 0.009) and longer disease duration (p = 0.007) were the only significant positive predictors of maintaining BMS at follow-up. The protective effect was stronger for patients taking DMT at both enrollment and follow-up (OR = 0.71; p = 0.006).

conclusionsThere is a need for development of more reliable prognostic indicators of BMS. Use of DMT was significantly associated with maintaining a benign disease state.

Indexed as

AdultDisability EvaluationFemaleHumansMaleMiddle AgedMultiple SclerosisNew YorkPrognosisRegistriesRetrospective StudiesTime FactorsBenign multiple sclerosisDisease courseDisease-modifying treatmentDMTMultiple sclerosis

Identifiers

PMID27416843
PMCPMC4946222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.